Calgary Depression Scale for Schizophrenia (CDSS) Test

For people living with schizophrenia who want to examine possible depressive features, the Calgary Depression Scale for Schizophrenia (CDSS) Test offers a structured way to review recent mood-related experiences. It can support clearer discussion when assessing depression among people with schizophrenia, bringing emotional, cognitive, sleep-related, and safety-relevant signs into one result. This summary reflects the pattern and intensity of depressive experiences covered by the items.

What This Assessment Explores

Depressive symptoms can overlap with reduced motivation, social withdrawal, and other negative experiences associated with schizophrenia. The questions focus on emotional and cognitive signs that may point toward depression, alongside sleep changes and functioning. As a depression scale for schizophrenia, it helps a person review whether these experiences are present and how strongly they affect recent life.

The result brings together these thematic areas:

• Depressed mood and observed affect show sadness, gloom, reduced expression, and visible low mood.
• Hopelessness and self-worth reflect views of the future and personal value.
• Guilt and ideas of accusation capture self-blame, feeling blamed, or feeling falsely accused.
• Sleep and suicide-related experiences cover early waking, morning worsening, and suicidal thoughts, plans, or attempts.

Together, the themes describe a depressive pattern. The result indicates whether endorsed experiences fall in the lower range or the range labelled depressive symptoms.

Methodology and Scientific Basis

Response options follow four ordered levels: absent, mild, moderate, or severe. Depression and morning depression use two weeks; hopelessness, one week; early waking, weekly frequency; several items lack an explicit window. The ninth item is interviewer-rated in the source instrument; an online self-report version cannot provide the same observational input.

The evidence base concerns depressive symptoms in schizophrenia through the Calgary Depression Scale (Addington et al., 1992), a published instrument designed to assess severity and distinguish depression from negative or other symptoms. The 1993 and 1994 Addington papers examined clinical use and specificity, and Porter et al. (2022) synthesised reliability findings. This questionnaire is conceptually consistent with that instrument, but the cited studies do not establish identical validation or standardisation for this online presentation.

The total is reported on 0-27, with result bands None to low (0-6) and Depressive symptoms (7-27). Levels indicate increasing severity, but individual response weights are unstated for this online questionnaire, so no point-by-point scoring rule should be inferred. Current distress, recall, and willingness to disclose may affect responses. The result indicates symptom severity here, not a standalone diagnosis.